136 related articles for article (PubMed ID: 15996092)
1. Bioavailability of higher dose MTX comparing oral and subcutaneous administration in patients with RA.
Rau R
J Rheumatol; 2005 Jul; 32(7):1412; author reply 1412-3. PubMed ID: 15996092
[No Abstract] [Full Text] [Related]
2. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2004 Apr; 31(4):645-8. PubMed ID: 15088287
[TBL] [Abstract][Full Text] [Related]
3. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
[TBL] [Abstract][Full Text] [Related]
4. Limitations of the study of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: comment on the article by Braun et al.
Raghu P; Grover PS; Kumar A
Arthritis Rheum; 2008 Jul; 58(7):2209; author reply 2209-10. PubMed ID: 18576338
[No Abstract] [Full Text] [Related]
5. [Subcutaneous self-administration of methotrexate in rheumatoid arthritis].
Huisman AM; Schouten JP; van Paassen HC; Wouters JM; Jacobs JW
Ned Tijdschr Geneeskd; 1996 Jul; 140(30):1564-5. PubMed ID: 8765767
[No Abstract] [Full Text] [Related]
6. Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis.
Schiff MH; Sadowski P
Rheumatol Int; 2017 Feb; 37(2):213-218. PubMed ID: 28012023
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis.
Hameed B; Jones H
Int J Rheum Dis; 2010 Oct; 13(4):e83-4. PubMed ID: 21199461
[No Abstract] [Full Text] [Related]
8. Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials.
Parker CT; Mewshaw E; Dennis GJ
J Am Osteopath Assoc; 2004 Jan; 104(1):7-8. PubMed ID: 14992316
[No Abstract] [Full Text] [Related]
9. Parenteral methotrexate for the treatment of rheumatoid arthritis.
Yazici Y; Bata Y
Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():46-8. PubMed ID: 24219041
[TBL] [Abstract][Full Text] [Related]
10. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
Khanna D; Park GS; Paulus HE; Simpson KM; Elashoff D; Cohen SB; Emery P; Dorrier C; Furst DE
Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate revisited: considerations for subcutaneous administration in RA.
Jay R
Clin Rheumatol; 2015 Feb; 34(2):201-5. PubMed ID: 25433918
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.
Schiff MH; Jaffe JS; Freundlich B
Ann Rheum Dis; 2014 Aug; 73(8):1549-51. PubMed ID: 24728329
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis.
Li D; Yang Z; Kang P; Xie X
Semin Arthritis Rheum; 2016 Jun; 45(6):656-62. PubMed ID: 26686022
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
[TBL] [Abstract][Full Text] [Related]
15. Inadequate response or intolerability to oral methotrexate: Is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?
Yadlapati S; Efthimiou P
Rheumatol Int; 2016 May; 36(5):627-33. PubMed ID: 26936262
[TBL] [Abstract][Full Text] [Related]
16. Comment on: Use of parenteral methotrexate significantly reduces the need for biological therapy.
Thornton C; Ong V; Ward J; Kennedy N; Steuer A
Rheumatology (Oxford); 2008 Sep; 47(9):1438; author reply 1438. PubMed ID: 18617550
[No Abstract] [Full Text] [Related]
17. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate.
Pichlmeier U; Heuer KU
Clin Exp Rheumatol; 2014; 32(4):563-71. PubMed ID: 24983446
[TBL] [Abstract][Full Text] [Related]
19. Self-injection of gold and methotrexate.
Arthur V; Jubb R; Homer D
J Rheumatol; 2001 Jan; 28(1):212. PubMed ID: 11196528
[No Abstract] [Full Text] [Related]
20. [Methotrexate: mainstay of rheumatoid arthritis treatment].
Jacobs JW; Bijlsma JW
Ned Tijdschr Geneeskd; 2009; 153():A879. PubMed ID: 19785862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
